Sawyers Charles Lazelle Buys Shares of ONC
Sawyers Charles Lazelle purchased 18,980 shares of ONC on June 11, 2026.
Key Points
- Sawyers Charles Lazelle purchased 18,980 shares of ONC on June 11, 2026, at a price of $0.0 per share.
- ONC shares traded at $264.48, with major funds like Baker Bros. Advisors holding 8,799,053 shares.
- Analysts maintain a positive outlook with RBC Capital setting a $436 price target on June 2, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Sawyers Charles Lazelle made a notable purchase of 18,980 shares of ONC on June 11, 2026. The transaction was executed at a price of $0.0 per share, indicating a non-cash acquisition. This move comes as ONC shares traded at $264.48.
Other Institutional Activity in ONC
Baker Bros. Advisors LP maintained its position in ONC with 8,799,053 shares valued at approximately $2.61 billion. Meanwhile, Primecap Management Co/CA/ slightly reduced its holdings by 5,400 shares, bringing its total to 4,975,181 shares worth about $1.48 billion. Capital International Investors significantly cut its stake by 955,140 shares, ending with 4,158,726 shares valued at $1.23 billion. FMR LLC also reduced its position by 299,017 shares, holding 3,693,610 shares worth $1.10 billion. On the other hand, Citadel Advisors LLC increased its holdings by 516,719 shares, nearly doubling its stake to 1,050,236 shares valued at $306.58 million.
BeOne Medicines AG Stock Down 27.9%
ONC shares recently traded at $264.48. The stock's performance is closely watched by investors, with a 52-week range that has seen significant fluctuations. Major institutional investors hold substantial positions, indicating confidence in the company's potential.
$ONC stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at BeOne Medicines AG
Several insiders made purchases on June 11, 2026. Shalini Sharp acquired 18,980 shares, Xiaodong Wang bought 193,492 shares, and Chan Henry Lee, the Senior Vice President and General Counsel, purchased 45,071 shares. These transactions were not part of any pre-planned trading programs.
Analysts Set New Price Targets
On June 2, 2026, RBC Capital maintained its 'buy' rating for ONC, setting a price target of $436. Leerink Partners and Guggenheim also maintained 'buy' ratings, with targets of $367 and $420, respectively. Barclays and Truist Securities echoed similar sentiments with 'buy' ratings and targets of $409 and $413. Wells Fargo initiated coverage with a 'buy' rating and a $400 target, while Wolfe Research started with a $340 target. Jefferies downgraded the stock to 'hold' with a $290 target on March 16, 2026.
Bottom Line
The recent insider purchase by Sawyers Charles Lazelle highlights ongoing interest in ONC. With significant institutional holdings and positive analyst ratings, ONC remains a stock to watch. Investors are reminded that insider purchases can reflect confidence but do not guarantee future performance.
Get BeOne Medicines AG alerts
New 13F filings, insider trades, and analyst moves on $ONC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.